CEBPB and hepatocellular carcinoma: Metformin reduced CD133 expression in the HCC cell lines HepG2, JHH6, JHH7, and Huh1, and these effects were associated with the adenosine monophosphate (AMP)-activated protein kinase (AMPK)/CCAAT/enhancer-binding protein beta (CEBPβ) signaling pathway.